Opinion|Videos|June 9, 2025
Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions
Author(s)Quoc-Dien Trinh, MD, MPH
Research highlights the effectiveness and safety of mHSPC treatments for black men, ensuring they receive appropriate care and reassurance.
Advertisement
Episodes in this series
Clinical Implications for Patient Care
Key Themes:
- Study findings directly inform the treatment of Black men with prostate cancer.
- Results confirm drug efficacy in this specific population.
- Data support equal eligibility of Black men for darolutamide treatment.
- Findings provide reassurance regarding a comparable benefit-risk profile.
Key Points for Physicians:
- Confidently recommend darolutamide to eligible Black patients.
- Use these data to address potential concerns about efficacy in diverse populations.
- Reassure patients regarding a comparable benefit-risk profile across racial groups.
Notable Insights: These findings provide clinicians with specific, evidence-based information to address potential concerns from clinicians and patients about treatment efficacy in Black men.
Clinical Significance: The confirmed efficacy and safety in Black men support equitable treatment recommendation practices and may help reduce disparities in advanced therapeutic approaches.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5